½ÃÀ庸°í¼
»óÇ°ÄÚµå
1519789
´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)Needle-free Drug Delivery Technology Market by Product, Application, End User, and Region 2024-2032 |
¼¼°èÀÇ ´Ïµé ÇÁ¸® ¾à¹°Àü´Þ ±â¼ú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 44¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 67¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4.56%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇÏ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ È®»ê, °í·É Àα¸ Áõ°¡, ÃÖ±Ù ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ ¹Ù´Ã ¾ø´Â ÁÖ»ç ±â¼ú(NFIT)ÀÇ °³¹ßÀº ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ±âÁ¸ÀÇ ÁÖ»ç ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê°í ȯÀÚ¿¡°Ô ¾à¹°À» Åõ¿©ÇÏ´Â ¹æ¹ýÀ» ¸»ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¸¶ÀÌÅ©·Î ³ëÁñ Á¦Æ® ÀÎÁ§ÅÍ, °æÇÇ ÆÐÄ¡, ÈíÀÔ±â, ÀÏȸ¿ë Ä«Æ®¸®Áö ÀÎÁ§ÅÍ, ºñ° ½ºÇÁ·¹ÀÌ, ÃÊÀ½ÆÄ µîÀÌ Æ÷ÇԵ˴ϴÙ. À̵éÀº ¿¹¹æÁ¢Á¾, Àν¶¸° Åõ¿©, ÅëÁõ °ü¸®, È£¸£¸ó ¿ä¹ý, ¾Ë·¹¸£±â, ¾Ï, È£Èí±â Áúȯ ¹× ±âŸ ¸¸¼ºÁúȯ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ¹Ù´ÃÀ» »ç¿ëÇÏ´Â Àü´Þ ½Ã½ºÅÛ°ú ºñ±³ÇÏ¿© ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ÅëÁõÀ» ÁÙÀÌ°í, ºÒÆíÇÔ°ú ºÒ¾ÈÀ» ÃÖ¼ÒÈÇϸç, ÆíÀǼºÀ» ³ôÀÌ°í, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ°í, º¹¿ë·®À» ¸ÂÃãÈÇÒ ¼ö ÀÖÀ¸¸ç, ºÎ»ó°ú °¨¿°ÀÇ À§ÇèÀ» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´õ ºü¸¥ ¾à¹°Àü´ÞÀ» ÅëÇØ ¾à¹°ÀÇ Èí¼ö¸¦ ÃËÁøÇÏ°í ÇÕº´ÁõÀ» ÃÖ¼ÒÈÇϸç Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº À¯ÇØ Æó±â¹° ¹ß»ýÀ» ÃÖ¼ÒÈÇÏ°í, Á¦Á¶½Ã ¹èÃâÀ» ÁÙÀ̸ç, Á¦Ç° Æó±â Çʿ伺À» ¾ø¾Ö±â ¶§¹®¿¡ ȯ°æ Ä£ÈÀûÀÔ´Ï´Ù.
´ç´¢º´, ¾Ï, Å©·Ðº´, ´Ù¹ß¼º °æÈÁõ, °üÀý¿°, °ñ´Ù°øÁõ, ½ÉÇ÷°ü Áúȯ(CVDs)°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¹«Ä§ ¾à¹°Àü´Þ ±â¼úÀº ÅëÁõÀ̳ª ºÒÆíÇÔ ¾øÀÌ ¸¸¼ºÁúȯ ȯÀÚ¿¡°Ô Àν¶¸°°ú ¾à¹°À» Àü´ÞÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀ̸ç ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃÅ°´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ º¹¾à ¼øÀÀµµ Çâ»ó, ¾à¹° Èí¼ö Áõ°¡, Ä¡·á È¿°ú Çâ»ó, ÁÖ»ç¹Ù´Ã·Î ÀÎÇÑ ÇÕº´Áõ ÃÖ¼Òȸ¦ ¸ñÀûÀ¸·Î ÇÏ´Â ±â¼úÀÇ º¸±ÞÀÌ ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ±Ù ·¹ÀÌÀú¸¦ ÀÌ¿ëÇØ ÇǺο¡ ¹Ì¼¼ÇÑ ¾à¹°À» Á¤¹ÐÇÏ°Ô ºÐ»çÇÏ´Â ¹«Ä§ÁÖ»ç ±â¼ú(NFIT)ÀÇ ¹ßÀüÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀεµÀûÀÌ°í ½ºÆ®·¹½º ¾ø´Â ¹æ½ÄÀ¸·Î µ¿¹°¿¡°Ô ¹é½Å, ¾à¹°, ¸¶ÃëÁ¦¸¦ Åõ¿©Çϱâ À§ÇØ µ¿¹° ÀÇ·á ºÐ¾ß¿¡¼ ±â¼ú È°¿ëÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿Í´Â º°µµ·Î, ¹Ù´Ã ¾ø´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í ÷´Ü ±â¼ú °³¹ßÀ» Áö¿øÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ ±¸»óÀÇ ½ÃÇàÀº ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ¹àÀº Àü¸ÁÀ» Á¦½ÃÇÏ°í ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â Àü¿°º´ À¯ÇàÀ¸·Î ÀÎÇÑ ¹é½Å ¼ö¿ä Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß È°µ¿, ¹«Ä§Åõ ¾à¹°Àü´Þ ±â¼úÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀÎ½Ä Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global needle-free drug delivery technology market size reached US$ 4.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.56% during 2024-2032. The escalating prevalence of chronic diseases, the increasing geriatric population, and the recent development of laser-powered needle-free injection technology (NFIT) represent some of the key factors driving the market.
Needle-free drug delivery technology refers to a method of administering medications to patients without using traditional needles. It includes micronozzle jet injectors, transdermal patches, inhalers, disposable cartridge injectors, nasal sprays, and ultrasound waves. They are widely used for vaccinations, insulin delivery, pain management, hormone therapy, and treating allergies, cancer, respiratory conditions, and other chronic diseases. As compared to traditional needle-based delivery systems, needle-free drug delivery technology reduces pain, minimizes discomfort and anxiety, enhances convenience, improves patient compliance, allows dosage customization, and prevents the risk of injuries and infections. It also offers faster medication delivery and aids in enhancing drug absorption, minimizing complications, and increasing treatment effectiveness. Needle-free drug delivery technology is also eco-friendly as it minimizes hazardous waste generation, reduces manufacturing emissions, and eliminates the need for product disposal.
The escalating prevalence of chronic diseases, such as diabetes, cancer, Crohn's disease, multiple sclerosis, arthritis, osteoporosis, and cardiovascular diseases (CVDs), is one of the primary factors driving the market growth. Needle-free drug delivery technology is widely used to deliver insulin and medications to chronic disease patients without pain and discomfort, which improves treatment outcomes, reduces the risk of infections, and enhances patients' quality of life. Furthermore, the widespread technology adoption to improve medication adherence, increase drug absorption, enhance treatment effectiveness, and minimize complications associated with needles is acting as another growth-inducing factor. Additionally, the recent development of a laser-powered needle-free injection technology (NFIT), which utilizes a laser-based system to blast microscopic jets of drugs into the skin with high precision, is positively influencing the market growth. Moreover, increasing technology utilization in veterinary care to administer vaccines, medications, and anesthesia to animals in a humane and stress-free manner is favoring the market growth. Apart from this, the implementation of various government initiatives to promote the adoption of needle-free drug delivery systems and support the development of advanced technologies are creating a positive outlook for the market growth. Other factors, including rising demand for vaccines due to the increasing prevalence of infectious diseases, increasing geriatric population, significant growth in the healthcare industry, extensive research and development (R&D) activities, and growing consumer awareness regarding the benefits of needle-free drug delivery technology, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global needle-free drug delivery technology market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, application, and end user.
Inhaler
Jet Injector
Novel Needles
Transdermal Patch
Others
The report has provided a detailed breakup and analysis of the needle-free drug delivery technology market based on the product. This includes inhaler, jet injector, novel needles, transdermal patch, and others.
Vaccine Delivery
Pain Management
Insulin Delivery
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the application has also been provided in the report. This includes vaccine delivery, pain management, insulin delivery, and others.
Hospitals and Clinics
Homecare Settings
Research Laboratories
Academics
Others
A detailed breakup and analysis of the needle-free drug delivery technology market based on the end user has also been provided in the report. This includes hospitals and clinics, homecare settings, research laboratories, academics, and others.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for needle-free drug delivery technology. Some of the factors driving the North America needle-free drug delivery technology market included the increasing prevalence of chronic diseases, the implementation of various government initiatives, and rapid technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global needle-free drug delivery technology market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.